The view on drug pricing from Wall Street, a pharma-friendly Dem holds firm, and what’s next for a big telehealth bill
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.
Drug makers are divided
Pharma has been clear with reporters and Hill staff that Democrats’ drug pricing bill will be catastrophic for the industry. But I always like to listen to what the companies are telling investors, as the story isn’t necessarily the same. Keep in mind that different companies have different exposure here, but I’ve compiled some tidbits from a few recent earnings calls:
